Improving recognition and management of inpatient delirium in Parkinson’s disease: evidence review and implications for clinical care
Authors:
Open Access
- 29 October 2025
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 17, 1693827
Abstract
Delirium is an acute disturbance of attention, arousal, and cognition that fluctuates in severity and is a common yet under recognized complication in hospitalized patients with Parkinson’s disease. In Parkinson’s disease, symptoms such as rigidity, bradykinesia, hallucinations, and slowed thinking overlap with the clinical features of delirium, which can obscure its onset in hospitalized patients. Variability in diagnostic criteria further complicates accurate recognition and prevalence estimates. This mini review summarizes current evidence on the prevalence, risk factors, and consequences of delirium in Parkinson’s disease (PD) and its associations with mortality and institutionalization. A total of 61 reports published between 1990 and 2025 were included across five domains: delirium diagnosis and prevalence, delirium subtypes, PD-specific delirium rates, risk factors and prevention, and treatment considerations. Foundational evidence reviews and official diagnostic documents (e.g., ICD-10, ICD-11, DSM criteria) were also incorporated as they remain internationally recognized standards for delirium diagnosis. Scholarly studies were appraised using the Joanna Briggs Institute (JBI) Critical Appraisal Checklists, with overall evidence quality judged to be moderate to high, while official diagnostic and guideline documents were considered high-quality based on their authoritative, consensus-driven development. Standardized clinical strategies for hospital management remain limited, but the available evidence supports the use of tailored approaches. We present evidence-based implications for clinical care aligned with the Parkinson’s Foundation Hospital Care Standards to improve recognition, prevention, and treatment. We emphasize the need for critical evaluation, methodological consistency, and acknowledgment of the dynamic care challenges posed by delirium in Parkinson’s disease.Keywords
This publication has 73 references indexed in Scilit:
- Discontinuation of the Clozapine Risk Evaluation and Mitigation Strategy and Implications in Movement DisordersMovement Disorders Clinical Practice, 2025
- The phenotype of delirium based on a close reading of diagnostic criteriaInternational Journal of Geriatric Psychiatry, 2023
- Non-pharmacological interventions for preventing delirium in hospitalised non-ICU patientsCochrane Database of Systematic Reviews, 2021
- Effect of Haloperidol on Survival Among Critically Ill Adults With a High Risk of DeliriumJAMA, 2018
- Association of Antipsychotic Use With Mortality Risk in Patients With Parkinson DiseaseJAMA Neurology, 2016
- Ramelteon for Prevention of Delirium in Hospitalized Older PatientsJAMA, 2015
- Effectiveness of Multicomponent Nonpharmacological Delirium InterventionsJAMA Internal Medicine, 2015
- Preventive Effects of Ramelteon on DeliriumJAMA Psychiatry, 2014
- The prevalence, incidence and risk factors for delirium in Dutch nursing homes and residential care homesInternational Journal of Geriatric Psychiatry, 2011
- Benzodiazepines for deliriumCochrane Database of Systematic Reviews, 2009